VSL#3 and Spontaneous Bacterial Peritonitis
Information source: Nottingham University Hospitals NHS Trust
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Decompensated Cirrhosis With Ascites.
Intervention: cotrimoxazole (Drug); VSL#3 active (Drug); VSL#3 placebo (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Nottingham University Hospitals NHS Trust Official(s) and/or principal investigator(s): Martin W James, BM BS FRCP PhD, Principal Investigator, Affiliation: NUH NHS Trust
Overall contact: Martin W James, BM BS FRCP PhD, Phone: +44 115 9249924, Ext: 63443, Email: martin.james@nuh.nhs.uk
Summary
Research question: Do oral probiotics in patients with cirrhosis and ascites reduce
intestinal bacterial concentrations, ascitic bacterial DNA, SBP and bacteraemia compared to
antibiotics or placebo?
This study is designed to investigate the effects of an oral probiotic (VSL#3; a mixture of
"healthy" bacteria for the intestines) compared to an antibiotic or placebo in preventing
infection developing in the abdominal fluid ("ascites") that collects in patients with
advanced liver disease ("cirrhosis"). Patients already having had infection will be excluded
from the study. Clear inclusion and exclusion criteria will be met and patients will be
monitored throughout the study to examine whether they have required more hospitalisations,
their rate infection in abdominal fluid or elsewhere and the level of liver function.
Clinical Details
Official title: The Effect of Probiotics on the Incidence of Spontaneous Bacterial Peritonitis in Patients With Cirrhosis and Ascites
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Liver-related mortality and liver related morbidity
Secondary outcome: Incidence of SBP, variceal bleeding, any non-SBP sepsis (e.g. pneumonia, urinary tract infection), clinical episodes of encephalopathy and the incidence of C. difficile infection.
Detailed description:
The prevalence of cirrhosis is increasing in the UK. Decompensation heralds a poor outcome,
with mortality in those developing ascites approximately 50% over the following 1-2 years.
Spontaneous bacterial peritonitis (SBP) in ascitic fluid further reduces survival and occurs
due to a combination of increased intestinal epithelial dysfunction, bacterial translocation
to mesenteric lymph nodes and ascitic fluid, and reduced opsonisation and neutrophil
function. Even with antibiotic treatment, 3-month mortality from SBP is approximately 40%
and results in expensive in-patient care. Several studies have confirmed the benefit of
secondary prophylaxis with long-term oral antibiotics in patients with advanced liver
disease (e. g. norfloxacin, co-trimoxazole) and others suggest that in patients at high risk
of developing SBP, primary antibiotic prophylaxis improves rates of sepsis and survival.
Problems with these strategies include emergence of bacterial resistance, and development
of antibiotic-associated diarrhoea (including C. difficile infection, which has a high
case-fatality rate in those with cirrhosis). Local bacterial resistance profiles and
association with C. difficile infection favour the choice of co-trimoxazole in our study
population. Patients with advanced cirrhosis taking co-trimoxazole have previously
demonstrated reduced liver-related outcomes such as infection and death3. Probiotic
preparations alter intestinal bacterial flora and improve intestinal barrier and neutrophil
function. Faecal bacterial counts of E. coli and Streptococcus (organisms commonly
responsible for SBP) showed a 2-log fall with probiotics, although whether they could reduce
the incidence of SBP remains unexamined.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Participant is willing and able to give informed consent for participation in the
study.
- Male or Female, aged 18 years or above.
- Diagnosed with required disease/severity/symptoms as outlined in 6. 3.1.
- Stable dose of current regular medication (e. g. diuretics, beta-blockers, vitamin
supplementation) for at least 4 weeks prior to study entry.
- Female participants of child bearing potential and male participants whose partner is
of child bearing potential must be willing to ensure that they or their partner use
effective contraception during the study and for 3 months thereafter
- Participants have clinically acceptable laboratory tests and ECG within 14 days of
enrolment.
- Able (in the Investigators opinion) and willing to comply with all study
requirements.
Willing to allow their General Practitioner and consultant
Exclusion criteria:
- Female participants who is pregnant, lactating or planning pregnancy during the
course of the study.
- Presence of hepatocellular carcinoma
- Scheduled elective surgery or other procedures requiring general anaesthesia during
the study.
- Participant who is terminally ill
- Any other significant disease or disorder which, in the opinion of the Investigator,
may either put the participants at risk because of participation in the study, or may
influence the result of the study, or the participant's ability to participate in the
study.
- Use of antibiotics or probiotics in the last 2 weeks
- Known hypersensitivity to trimethoprim, sulphonamides or any other ingredients in
co-trimoxazole tablet.
- History of acute porphyria or serious haematological disorder.
- Participants who have participated in another research study involving an
investigational product in the past 12 weeks
Locations and Contacts
Martin W James, BM BS FRCP PhD, Phone: +44 115 9249924, Ext: 63443, Email: martin.james@nuh.nhs.uk
NUH NHS Trust, Nottingham, Nottinghamshire NG7 2UH, United Kingdom; Recruiting Brian Thomson, PhD, Phone: +44 1159709049, Email: brian.thomson@nottingham.ac.uk Maria Koufali, PhD, Phone: +44 1159709049, Email: maria.koufali@nuh.nhs.uk
Additional Information
Starting date: February 2012
Last updated: October 4, 2012
|